A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice

Mitsumasa Saito, Sayo Yamamoto, Kinuyo Ozaki, Yukiko Tomioka, Haruka Suyama, Masami Morimatsu, Ken ichi Nishijima, Shin ichi Yoshida, Etsuro Ono

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Group B Streptococcus (GBS) is a leading cause of invasive bacterial infections in human newborns. A key GBS virulence factor is its capsular polysaccharide (CPS), possessing terminal sialic acid residues that suppress host immune response and provide a survival advantage to the pathogen. CPS binds to Siglec-9 expressed on neutrophils, which is expected to down-regulate the immune responsiveness of neutrophils. We hypothesized that a soluble form of Siglec-9 (sSiglec-9) competitively inhibits a binding of CPS to Siglec-9 on immune cells, leading to provide antibacterial benefit against GBS infection in the transgenic mouse line expressing sSiglec-9 (sSiglec-9 Tg). The sSiglec-9 in the sera of sSiglec-9 Tg bound to the sialylated-GBS strains belonging to serotypes Ia, Ib, II, III, IV and V in whole GBS cell ELISA. When GBS cells of serotype III that is a common serotype in late-onset GBS disease (LOD) were intraperitoneally inoculated into sSiglec-9 Tg, sSiglec-9 Tg showed a significant resistance as compared with non-transgenic littermates. Furthermore, GBS serotype III organisms were not detected in cultures of the blood from surviving mice (<1 × 103 CFU/ml). These results indicated that sSiglec-9 Tg mice were more efficient in eliminating GBS and survived better after the intraperitoneal challenge with GBS serotype III bacteria.

Original languageEnglish
Pages (from-to)106-110
Number of pages5
JournalMicrobial Pathogenesis
Volume99
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
Streptococcus agalactiae
Transgenic Mice
Infection
Polysaccharides
Neutrophils
N-Acetylneuraminic Acid
Virulence Factors
Bacterial Infections

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Infectious Diseases

Cite this

A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice. / Saito, Mitsumasa; Yamamoto, Sayo; Ozaki, Kinuyo; Tomioka, Yukiko; Suyama, Haruka; Morimatsu, Masami; Nishijima, Ken ichi; Yoshida, Shin ichi; Ono, Etsuro.

In: Microbial Pathogenesis, Vol. 99, 01.10.2016, p. 106-110.

Research output: Contribution to journalArticle

Saito, M, Yamamoto, S, Ozaki, K, Tomioka, Y, Suyama, H, Morimatsu, M, Nishijima, KI, Yoshida, SI & Ono, E 2016, 'A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice', Microbial Pathogenesis, vol. 99, pp. 106-110. https://doi.org/10.1016/j.micpath.2016.08.014
Saito, Mitsumasa ; Yamamoto, Sayo ; Ozaki, Kinuyo ; Tomioka, Yukiko ; Suyama, Haruka ; Morimatsu, Masami ; Nishijima, Ken ichi ; Yoshida, Shin ichi ; Ono, Etsuro. / A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice. In: Microbial Pathogenesis. 2016 ; Vol. 99. pp. 106-110.
@article{008ab8d0ba8842c0b60f64c33f7d48b1,
title = "A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice",
abstract = "Group B Streptococcus (GBS) is a leading cause of invasive bacterial infections in human newborns. A key GBS virulence factor is its capsular polysaccharide (CPS), possessing terminal sialic acid residues that suppress host immune response and provide a survival advantage to the pathogen. CPS binds to Siglec-9 expressed on neutrophils, which is expected to down-regulate the immune responsiveness of neutrophils. We hypothesized that a soluble form of Siglec-9 (sSiglec-9) competitively inhibits a binding of CPS to Siglec-9 on immune cells, leading to provide antibacterial benefit against GBS infection in the transgenic mouse line expressing sSiglec-9 (sSiglec-9 Tg). The sSiglec-9 in the sera of sSiglec-9 Tg bound to the sialylated-GBS strains belonging to serotypes Ia, Ib, II, III, IV and V in whole GBS cell ELISA. When GBS cells of serotype III that is a common serotype in late-onset GBS disease (LOD) were intraperitoneally inoculated into sSiglec-9 Tg, sSiglec-9 Tg showed a significant resistance as compared with non-transgenic littermates. Furthermore, GBS serotype III organisms were not detected in cultures of the blood from surviving mice (<1 × 103 CFU/ml). These results indicated that sSiglec-9 Tg mice were more efficient in eliminating GBS and survived better after the intraperitoneal challenge with GBS serotype III bacteria.",
author = "Mitsumasa Saito and Sayo Yamamoto and Kinuyo Ozaki and Yukiko Tomioka and Haruka Suyama and Masami Morimatsu and Nishijima, {Ken ichi} and Yoshida, {Shin ichi} and Etsuro Ono",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.micpath.2016.08.014",
language = "English",
volume = "99",
pages = "106--110",
journal = "Microbial Pathogenesis",
issn = "0882-4010",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice

AU - Saito, Mitsumasa

AU - Yamamoto, Sayo

AU - Ozaki, Kinuyo

AU - Tomioka, Yukiko

AU - Suyama, Haruka

AU - Morimatsu, Masami

AU - Nishijima, Ken ichi

AU - Yoshida, Shin ichi

AU - Ono, Etsuro

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Group B Streptococcus (GBS) is a leading cause of invasive bacterial infections in human newborns. A key GBS virulence factor is its capsular polysaccharide (CPS), possessing terminal sialic acid residues that suppress host immune response and provide a survival advantage to the pathogen. CPS binds to Siglec-9 expressed on neutrophils, which is expected to down-regulate the immune responsiveness of neutrophils. We hypothesized that a soluble form of Siglec-9 (sSiglec-9) competitively inhibits a binding of CPS to Siglec-9 on immune cells, leading to provide antibacterial benefit against GBS infection in the transgenic mouse line expressing sSiglec-9 (sSiglec-9 Tg). The sSiglec-9 in the sera of sSiglec-9 Tg bound to the sialylated-GBS strains belonging to serotypes Ia, Ib, II, III, IV and V in whole GBS cell ELISA. When GBS cells of serotype III that is a common serotype in late-onset GBS disease (LOD) were intraperitoneally inoculated into sSiglec-9 Tg, sSiglec-9 Tg showed a significant resistance as compared with non-transgenic littermates. Furthermore, GBS serotype III organisms were not detected in cultures of the blood from surviving mice (<1 × 103 CFU/ml). These results indicated that sSiglec-9 Tg mice were more efficient in eliminating GBS and survived better after the intraperitoneal challenge with GBS serotype III bacteria.

AB - Group B Streptococcus (GBS) is a leading cause of invasive bacterial infections in human newborns. A key GBS virulence factor is its capsular polysaccharide (CPS), possessing terminal sialic acid residues that suppress host immune response and provide a survival advantage to the pathogen. CPS binds to Siglec-9 expressed on neutrophils, which is expected to down-regulate the immune responsiveness of neutrophils. We hypothesized that a soluble form of Siglec-9 (sSiglec-9) competitively inhibits a binding of CPS to Siglec-9 on immune cells, leading to provide antibacterial benefit against GBS infection in the transgenic mouse line expressing sSiglec-9 (sSiglec-9 Tg). The sSiglec-9 in the sera of sSiglec-9 Tg bound to the sialylated-GBS strains belonging to serotypes Ia, Ib, II, III, IV and V in whole GBS cell ELISA. When GBS cells of serotype III that is a common serotype in late-onset GBS disease (LOD) were intraperitoneally inoculated into sSiglec-9 Tg, sSiglec-9 Tg showed a significant resistance as compared with non-transgenic littermates. Furthermore, GBS serotype III organisms were not detected in cultures of the blood from surviving mice (<1 × 103 CFU/ml). These results indicated that sSiglec-9 Tg mice were more efficient in eliminating GBS and survived better after the intraperitoneal challenge with GBS serotype III bacteria.

UR - http://www.scopus.com/inward/record.url?scp=84983070858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983070858&partnerID=8YFLogxK

U2 - 10.1016/j.micpath.2016.08.014

DO - 10.1016/j.micpath.2016.08.014

M3 - Article

VL - 99

SP - 106

EP - 110

JO - Microbial Pathogenesis

JF - Microbial Pathogenesis

SN - 0882-4010

ER -